2 unchanged sentences
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
−Removed: As disclosed in the table below, during the first quarter of 2026, certain directors adopted a “Rule 10b5-1 trading arrangement”.
+Added: As disclosed in the table below, during the second quarter of 2026, certain directors adopted a “Rule 10b5-1 trading arrangement”.
This plan provides for the sale of our common stock and is intended to satisfy the affirmative defense in Rule 10b5-1(c).
1 unchanged sentence
Maximum Total Shares of Common Stock to be Sold Under the Plan (2)
−Removed: Alexander Schuth, M.D.
−Removed: Chief Operating and Financial Officer 3/27/2026 9/30/2027 144,051
+Added: Nancy Thornberry Director 6/3/2026 9/2/2027 35,377
__________________________________________________
1 unchanged sentence
(2) This amount represents the maximum total shares that could be sold under the plan, but the amounts may change for executive officers due to the sale of shares to satisfy tax withholding requirements.
−Removed: No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the first quarter ended March 31, 2026.
+Added: No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the second quarter ended June 30, 2026.
EXHIBIT INDEX
2 unchanged sentences
Number Filing Date
−Removed: 10.1 A mended and Restated Outside Director Compensation Policy
−Removed: — — — Filed herewith
−Removed: 10.2 Revenue Participation Right Purchase and Sale Agreement by and between Denali Therapeutics Inc.
−Removed: and Royalty Pharma Investments 2023 ICAV Dated as of December 2, 2025
+Added: 10.1 Asset Purchase Agreement, dated June 12, 2026
— — — Filed herewith
18 unchanged sentences
— — — Furnished herewith
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2026, formatted in Inline XBRL (contained in Exhibit 101)
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2026, formatted in Inline XBRL (contained in Exhibit 101)
— — — Furnished herewith
3 unchanged sentences
DENALI THERAPEUTICS INC.
−Removed: May 7, 2026 By:
+Added: August 6, 2026 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 7, 2026 By:
+Added: August 6, 2026 By:
/s/ Alexander O.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.